Navigation Links
Athera Receives Allowance of Two Key Patents
Date:10/14/2009

STOCKHOLM, October 14 /PRNewswire/ -- Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

Following subsequent grant the patents will be registered in the designated European countries, and there are corresponding patent applications pending worldwide. Together, the patents will provide strong protection for pharmaceutical uses of Annexin A5 for the prevention of plaque rupture, as well as use of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular disease.

"These European patents strengthens our efforts in building an attractive and competitive pharmaceutical product portfolio in cardiovascular disease," said Carina Schmidt, Athera Biotechnologies Chief Executive Officer. "I am convinced that the product candidates that Athera develops have the potential to fulfil important medical needs. We can see this also in a great interest from the pharmaceutical industry to explore partnering opportunities with Athera for future clinical developments."

Natural antibodies to phosphorylcholine (PC) are known to be cardio-protective and are antibodies to specific surface regions on OxLDL. High levels of antibodies against PC (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients. Later data from several studies confirm that low anti-PC levels predict an increased risk of CVD and even are linked to increased mortality in Acute Coronary Syndrome patients. The pharmaceutical product candidate, PC-mAb, is developed by Athera in collaboration with Dyax Corp. in Boston, USA (NASDAQ:DYAX). The biomarker product CVDefine(R), that has the potential to enable a "theranostics" approach in prevention of cardiovascular disease, is on the market and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

Athera's second novel product candidate, Annexin A5, is developed for prevention of plaque rupture and athero-thrombosis through binding of the protein to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction. Athera has an agreement with Richter-Helm BioLogics GmbH & Co. KG in Hamburg, Germany, for the process development of the product.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.

http://www.athera.se

Contact:

Carina Schmidt, CEO Phone: +46-70-552-5115, Mail: c.schmidt@athera.se

SOURCE Athera Biotechnologies AB


'/>"/>
SOURCE Athera Biotechnologies AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
2. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
3. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading ... today announced that it has been named to The Silicon Review’s “20 Fastest Growing ... other markets, Cambridge Semantics serves the needs of end users facing some of the ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage with biometrics ... for secure access, voice recognition for hands-free communication, and facial recognition to help ... biometrics technology today. But if they asked Joey Pritikin, Vice President of ...
(Date:4/27/2016)... ... April 27, 2016 , ... The ... announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined ... of the founding commercial leaders responsible for the commercialization of multiple orphan drug ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact ... Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET ... treatments in small animal subjects. Simultaneous PET/MRI imaging offers a solution to many ...
Breaking Biology Technology:
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
(Date:3/9/2016)... 9, 2016 Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> Nigeria ... that more than 23,000 public service employees either did ... receiving their salary unlawfully.    --> DERMALOG, ...
Breaking Biology News(10 mins):